253 related articles for article (PubMed ID: 34158591)
21. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy.
Zhao Q; Hu W; Xu J; Zeng S; Xi X; Chen J; Wu X; Hu S; Zhong T
Front Mol Biosci; 2022; 9():919274. PubMed ID: 35911954
[TBL] [Abstract][Full Text] [Related]
23. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
Li R; Huang B; Tian H; Sun Z
Front Oncol; 2022; 12():1096717. PubMed ID: 36698392
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response.
Lorenzo-Sanz L; Muñoz P
Cancer Microenviron; 2019 Dec; 12(2-3):119-132. PubMed ID: 31583529
[TBL] [Abstract][Full Text] [Related]
25. Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer.
Song J; Wei R; Huo S; Gao J; Liu X
Front Immunol; 2022; 13():920512. PubMed ID: 35769483
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy.
Zhang SY; Ren XY; Wang CY; Chen XJ; Cao RY; Liu Q; Pan X; Zhou JY; Zhang WL; Tang XR; Cheng B; Wu T
Front Oncol; 2021; 11():587862. PubMed ID: 34277389
[TBL] [Abstract][Full Text] [Related]
27. Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
Datar I; Schalper KA
Clin Cancer Res; 2016 Jul; 22(14):3422-4. PubMed ID: 27076625
[TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance.
Lawal B; Tseng SH; Olugbodi JO; Iamsaard S; Ilesanmi OB; Mahmoud MH; Ahmed SH; Batiha GE; Wu ATH
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439277
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
Front Immunol; 2022; 13():954616. PubMed ID: 35958586
[TBL] [Abstract][Full Text] [Related]
31. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression.
Zhang Z; Li L; Li M; Wang X
Comput Struct Biotechnol J; 2020; 18():2438-2444. PubMed ID: 32905022
[TBL] [Abstract][Full Text] [Related]
32. Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis.
Dzobo K; Sinkala M
OMICS; 2021 May; 25(5):313-332. PubMed ID: 33961518
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
Cho ES; Kang HE; Kim NH; Yook JI
Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
[TBL] [Abstract][Full Text] [Related]
34. Regulatory effects of lncRNAs and miRNAs on the crosstalk between autophagy and EMT in cancer: a new era for cancer treatment.
Si L; Yang Z; Ding L; Zhang D
J Cancer Res Clin Oncol; 2022 Mar; 148(3):547-564. PubMed ID: 35083552
[TBL] [Abstract][Full Text] [Related]
35. Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.
De Matteis S; Canale M; Verlicchi A; Bronte G; Delmonte A; Crinò L; Martinelli G; Ulivi P
J Oncol; 2019; 2019():7475364. PubMed ID: 31531020
[TBL] [Abstract][Full Text] [Related]
36. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
Front Oncol; 2021; 11():620674. PubMed ID: 33747932
[TBL] [Abstract][Full Text] [Related]
37. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.
Devecchi A; De Cecco L; Dugo M; Penso D; Dagrada G; Brich S; Stacchiotti S; Sensi M; Canevari S; Pilotti S
Cancer Commun (Lond); 2018 Nov; 38(1):70. PubMed ID: 30486883
[TBL] [Abstract][Full Text] [Related]
38. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
Hamilton DH; David JM; Dominguez C; Palena C
Cells Tissues Organs; 2017; 203(2):128-138. PubMed ID: 28214895
[TBL] [Abstract][Full Text] [Related]
39. Crosstalk between lipid metabolism and EMT: emerging mechanisms and cancer therapy.
Din ZU; Cui B; Wang C; Zhang X; Mehmood A; Peng F; Liu Q
Mol Cell Biochem; 2024 Apr; ():. PubMed ID: 38622439
[TBL] [Abstract][Full Text] [Related]
40. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.
Zhou Y; Li G; Li H; Lai F; Duan P; Cheng M
J Immunol Res; 2022; 2022():1377565. PubMed ID: 35836470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
